EN DE
Watch Advanced Biomed Inc. Common Stock for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Advanced Biomed Inc. (ADVB) fair value: what the stock is really worth

As of Oct 29, 2026: fair value (intrinsic value) of Advanced Biomed Inc. stock $3.51, price $2.64, upside +33.1%, quality 38 out of 100. Rating: undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · Based in Hong Kong

AB Advanced Biomed Inc. logo Thin data Oct 30, 2026

Advanced Biomed Inc.

ADVB · US
Speculative

The stock costs 25% less than our calculation considers fair.

Fair value $3.51 · Undervalued (25%)
Costs just 1.7 times its yearly profit.
Mixed vs. peers (4/8)
Quality 38/100
Weak Growth
Negative free cash flow
Narrow moat 42/100
Thin data
⚠ Dilution
Watch Advanced Biomed Inc. Common Stock for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$80.00 $2.64 Fair Value $3.51 Mar 2025 Oct 2026

White line = price, green steps = our fair value per fiscal year. As of Oct 30, 2026.

How to read this chart

20‑month range $2.64 – $80.00 · fair‑value band $2.64 – $4.54 · the $2.64 price screens below the $3.51 fair value. As of Oct 30, 2026.

Follow Advanced Biomed Inc. Common Stock in your weekly email

Every Wednesday you see whether Advanced Biomed Inc. Common Stock is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Advanced Biomed Inc., an investment holding company, engages in the research and development of microfluidic biochip technologies for precision oncology detection, diagnosis, and treatment in Taiwan.

Show moreShow less

Its devices include A+Pre, an automated sample preparation system that enables pre-concentration of diluted blood samples; AC-1000, a rare cell device to solve the problem of detection of hypercoagulable state samples of tumor patients; A+SCDrop, a circulating tumor cell (CTC) single-cell capture device; and A+CellScan, an analyzer with an immunostaining chip for immunostaining/analysis of the AC-1000 product.

The company also offers microfluidic biochips, such as A+Pre, AC-1000 CTC enrichment, and A+CellScan chips to provide assay products and services to cancer patients.

In addition, its immunochromogenic kits include A+CTCE kit to identify epithelial circulating tumor cells and determined by the immunochromogenicity of EpCAM, CK (pan), CD45, and CD14 antibodies; A+CTCM kit to identify mesenchymal circulating tumor cells based on the immunochromogenicity of Vimentin, CD45, and CD14 antibodies; A+EMT to identify epithelial-to-mesenchymal circulating tumor cells determined by the immunochromogenicity of cell-surface Vimentin, and CD45 and CD14 antibodies; and A+CM to identify tumor-associated macrophages based on the immunochromogenicity of PD-L1, CD45, and CD14 antibodies.

Further, the company is developing A+LCGuard for early screening of lung cancer. Additionally, it establishes and operates medical clinics in the People's Republic of China. The company was founded in 2014 and is headquartered in New York, New York.

Stock analysis

Advanced Biomed Inc. (ADVB) currently trades at $2.64, while our model-based Fair Value estimate is $3.51, implying the stock looks roughly 24.9% undervalued today.

Show more

Valuation

Bull case: the Multiples group reads highest at a median of $32.44 per share, and 9 of the 10 models we run sit above the $2.64 price.

Bear case: the Asset-Based group reads lowest at $7.43, and 1 of the 10 models stay below the price. Data coverage for this calculation is low.

Scenario range: $2.64 (bear) to $4.54 (bull), the price of $2.64 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 38/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak, negative or inconsistent.

Advanced Biomed Inc. Common Stock reported revenue of $128K in FY2026 versus $0 in FY2021. Reported net income was $6.7M in FY2026.

Key figures

Market cap $4.9M Micro · P/E ratio 1.7 · P/S ratio 88.0 · EPS (TTM) $−5.00 · Return on equity −79.5% · Return on assets (EBIT) −28.3% · Operating margin −3,856% · Revenue (TTM) $128K.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (medium confidence).

What moves the price

The share trades about 86% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −10% fair-value upside, at 33%, ADVB screens cheaper than that median.

Fair Value models

Bear $2.64 Fair Value $3.51 Bull $4.54
Price $2.64 · Upside +33.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Owner Earnings $42.32 $61.09 $87.02 64
P/E Multiple $66.68 $88.91 $111.14 63
Growth-Adj P/E $52.17 $74.53 $96.88 59
All 10 models by family
DCF Models
Owner Earnings $42.32 $61.09 $87.02 64
Earnings-Based
Graham-Dodd $27.48 $73.11 $95.58 51
Lynch FV $14.15 $20.21 $26.27 48
PEG = 1.0 $14.15 $20.21 $26.27 45
Multiples
P/E Multiple $66.68 $88.91 $111.14 63
P/S Multiple $0.2000 $0.2700 $0.3400 58
P/B Multiple $24.33 $32.44 $40.55 55
Asset-Based
NCAV (Graham) $4.90 $7.43 $9.29 52
Economic Profit
Residual Income $20.07 $24.47 $41.92 58
Growth Earnings
Growth-Adj P/E $52.17 $74.53 $96.88 59

The fair value above starts from this blend and is adjusted for dilution from new shares.

Open the full fair value analysis →

Quality Score breakdown

Overall quality 38/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 60
How much profit the company makes from its sales and capital
Quality Growth 77
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 52
Debt, balance sheet and risk of trouble
Investment 33
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Momentum 7
Price trend of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 10
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 7/100
Revenue growth is weak, negative or inconsistent.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
not computed

Watch ADVB, get fair value alerts →

Compare Advanced Biomed Inc. Common Stock with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 123 stocks

Beats the industry median on 4/7 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 38 · Bottom 25%
Fair Value upside +33.1% · Top 25%
Profitability
Return on assets 48.6% · Top 25%
Growth and dividend
Revenue growth (quarter YoY) 0.0% · Below median

Valuation Multiplesvs Diagnostics & Research median · lower = cheaper

P/E (12 months) 1.7× · Cheapest 25%
P/B 0.40× · Cheapest 25%
P/S (12 months) 38.57× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)77 · sector 0
FUTURE (revenue growth)0 · sector 40
PAST (return on equity)0 · sector 14
HEALTH (low debt)0 · sector 95
DIVIDEND (yield)0 · sector 32

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
WuXi AppTec Co 603259 ¥142.89 ¥164.66 +15% vs ADVB
IQVIA Holdings IQV $271.55 $298.71 +10% vs ADVB
Illumina, Inc ILMN $271.04 $297.04 +10% vs ADVB
Thermo Fisher Scientific Inc TMO $693.02 $686.04 −1% vs ADVB
Danaher Corporation DHR $232.00 $209.18 −10% vs ADVB
IDEXX Laboratories, Inc IDXX $570.21 $496.48 −13% vs ADVB
Mettler-Toledo International Inc MTD $1,670 $648.30 −61% vs ADVB
Agilent Technologies, Inc A $175.96 $64.53 −63% vs ADVB
Lonza Group LONN CHF 635.80 CHF 153.50 −76% vs ADVB
Waters Corporation WAT $455.98 $107.35 −76% vs ADVB

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Advanced Biomed Inc. Common Stock · Fair Value
$3.51 +25%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Advanced Biomed Inc. Common Stock Fair Value". https://www.fairvalue-calculator.com/stock/ADVB

Frequently asked questions

Is Advanced Biomed Inc. (ADVB) overvalued or undervalued?
As of Oct 30, 2026, our model estimates a fair value of $3.51 versus a price of $2.64, about +33% upside (undervalued).
What is the fair value of ADVB?
Our model-based fair value for Advanced Biomed Inc. Common Stock is $3.51 (as of Oct 30, 2026), built from audited fundamentals. The current price: $2.64.
What is the quality score of ADVB?
Advanced Biomed Inc. Common Stock has a Quality Score of 38/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Advanced Biomed Inc. (ADVB)?
Our model-based price target is the fair value of $3.51 (as of Oct 30, 2026) from 10 valuation models. Cautious scenario $2.64, optimistic scenario $4.54. It is a calculation from audited fundamentals, not an analyst target.
What is the Advanced Biomed Inc. Common Stock stock forecast for 2026?
Our models put fair value at $3.51, about +33% upside versus a price of $2.64 (undervalued). Cautious scenario $2.64, optimistic scenario $4.54. The calculation is refreshed regularly with new filings.
What is the revenue of Advanced Biomed Inc. (ADVB)?
Advanced Biomed Inc. Common Stock reported trailing-twelve-month revenue of about $128K (latest available figure, as of Oct 30, 2026).
What is the intrinsic value of Advanced Biomed Inc. (ADVB)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Advanced Biomed Inc. Common Stock it is $3.51 per share (as of Oct 30, 2026), against a price of $2.64. It is the blended result of 10 valuation models (cash flow, earnings, asset, dividend).
Is Advanced Biomed Inc. Common Stock stock overvalued or undervalued in 2026?
As of Oct 30, 2026, ADVB trades below its calculated fair value: price $2.64, fair value $3.51, a gap of about +33% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ADVB?
No. The price is what the market pays today ($2.64); the fair value is what the company's own numbers justify ($3.51). For Advanced Biomed Inc. Common Stock the two are $0.8740 per share apart. That gap is exactly why we show both numbers side by side.
How much is Advanced Biomed Inc. Common Stock worth?
The market values Advanced Biomed Inc. Common Stock at about $4.9M (market capitalisation, as of Oct 30, 2026). Per share that is $2.64; our models calculate a fair value of $3.51 per share.
What do the bullish and bearish scenarios say about ADVB?
Our models span a range for Advanced Biomed Inc. Common Stock: cautious scenario $2.64, base $3.51, optimistic $4.54 per share (as of Oct 30, 2026, price $2.64). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of ADVB?
Advanced Biomed Inc. Common Stock trades at a price-to-earnings ratio of 1.7 (as of Oct 30, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $3.51 is built from several models across several years. Other multiples: P/B 0.4, P/S 38.6.
How solid is the balance sheet of Advanced Biomed Inc. (ADVB)?
Balance-sheet figures for Advanced Biomed Inc. Common Stock (as of Oct 30, 2026): return on equity −79.5%. They feed the Quality Score of 38/100, which measures business quality independently of the share price.
How far is ADVB from its 52-week high?
Advanced Biomed Inc. Common Stock trades at $2.64, about 86% below its 52-week high of $18.98 and at the low of $2.64 (as of Oct 29, 2026). Distance from the high says nothing about value: that is what the fair value of $3.51 is for.
Which stocks are comparable to Advanced Biomed Inc. Common Stock?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Lonza Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Advanced Biomed Inc. Common Stock stock attractive at the current price?
The data as of Oct 30, 2026: price $2.64, calculated fair value $3.51 (+33%), Quality Score 38/100, from 10 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ADVB calculated?
We run Advanced Biomed Inc. Common Stock through 10 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $3.51, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.1 % above its aggregate fair value. Advanced Biomed Inc. Common Stock currently trades 25 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Advanced Biomed Inc. (ADVB)?
The closing price on Oct 29, 2026 was $2.64. Our model-based fair value is $3.51, about +33% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Advanced Biomed Inc. Common Stock right now?
The large discount to fair value meets weak quality (38/100). That raises the risk this is a value trap rather than a bargain. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Advanced Biomed Inc. Common Stock

How large is the market capitalisation of Advanced Biomed Inc. (ADVB)?
The market capitalisation of Advanced Biomed Inc. Common Stock is $4.9M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Advanced Biomed Inc. (ADVB)?
The price-to-sales ratio of Advanced Biomed Inc. Common Stock is 88.0 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Advanced Biomed Inc. (ADVB)?
Earnings per share at Advanced Biomed Inc. Common Stock are $−5.00 (price ÷ EPS = P/E 1.7). Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Advanced Biomed Inc. (ADVB)?
The return on equity (ROE) of Advanced Biomed Inc. Common Stock is −79.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Advanced Biomed Inc. (ADVB)?
On an EBIT basis the return on assets of Advanced Biomed Inc. Common Stock is −28.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Advanced Biomed Inc. (ADVB)?
The operating margin of Advanced Biomed Inc. Common Stock is −3,856% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How much free cash flow does Advanced Biomed Inc. (ADVB) generate?
The free cash flow of Advanced Biomed Inc. Common Stock is −$1.9M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Advanced Biomed Inc. (ADVB) hold?
Advanced Biomed Inc. Common Stock holds more cash than debt, $352K net (fiscal year 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Advanced Biomed Inc. Common Stock in the live analysis

One click puts Advanced Biomed Inc. Common Stock on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.